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Background: Preclinical diastolic dysfunction (PDD) is defined as normal systolic function, moderate or severe diastolic dysfunction determined 
by Doppler criteria but no symptoms of heart failure (HF). The physiological phenotype of patients with PDD remains poorly defined especially with 
regard to the kidney which plays a key role in HF prognosis and progression. Our objective was to determine the physiological phenotype of patients 
with PDD as compared to those with preclinical systolic dysfunction (PSD) as defined by LVEF < 45% without symptoms of HF. Based upon studies in 
experimental renal insufficiency which has resulted in cardiac fibrosis and diastolic dysfunction, we hypothesized that PDD is characterized by renal 
impairment even in the absence of symptoms of HF.
Methods: We prospectively performed detailed physiological phenotyping of subjects with PDD (n=18) and PSD (n=20). Each subject was 
maintained on a 120 mEq sodium/day diet and had detailed neurohumoral assessment and renal clearance studies with iothalmate and PAH to 
measure glomerular filtration rate (GFR) and renal plasma flow (RPF) respectively. Values provided are mean±SEM. (*p<0.05 PDD vs PSD)
Results: PDD was characterized by preserved LV systolic function (63±5 vs 39±11 %*), smaller LV systolic* and diastolic* volume index and 
higher systolic blood pressure (133±15 vs119±11mm Hg*) as compared to PSD. Importantly both GFR (54±3 vs 76±5* ml/min/1.73m2) and RPF 
(266±15 vs 366±27* ml/min/1.73m2) was significantly reduced in PDD as compared to PSD. 24-hour urinary sodium excretion (111±9 vs 135±10 
mol/24 hours) was maintained in PDD and similar to PSD. Both PDD and PSD subjects had similarly elevated ANP, BNP, renin and norepinephrine.
Conclusion: The clinical phenotype of PDD is impaired renal hemodynamic function with reduced GFR and RPF in association with increased 
arterial pressure as compared to PSD. We speculate that a principal mechanism for the development of PDD may be impaired renal function 
consistent with a “kidney-heart connection.” Therapeutic strategies therefore to delay the progression of PDD need to target both the kidney and the 
heart.
